Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806)

被引：0

作者：

Taniguchi, Hiroya

Yagisawa, Masataka

Satoh, Taroh

Kadowaki, Shigenori

Sunakawa, Yu

Nishina, Tomohiro

Komatsu, Yoshito

Esaki, Taito

Sakai, Daisuke

Doi, Ayako

Kajiwara, Takeshi

Ono, Hiromi

Asano, Masatoshi

Hirano, Nami

Odegaard, Justin Iver

Fujii, Satoshi

Nomura, Shogo

Sato, Akihiro

Yoshino, Takayuki

Nakamura, Yoshiaki

机构：

[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[2] Japanese Red Cross Kitami Hosp, Kitami, Hokkaido, Japan

[3] Osaka Univ Hosp, Palliat & Support Care Ctr, Suita, Osaka, Japan

[4] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[5] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan

[6] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan

[7] Hokkaido Univ Hosp, Div Canc Chemotherapy, Sapporo, Hokkaido, Japan

[8] Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[9] Osaka Univ Hosp, Ctr Canc Genom & Personalized Med, Osaka, Japan

[10] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Chiba, Japan

[11] Guardant Hlth Inc, Redwood City, CA USA

[12] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Yokohama, Kanagawa, Japan

[13] Univ Tokyo, Grad Sch Med, Dept Biostat & Bioinformat, Tokyo, Japan

[14] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3014

引用

页数：1

共 9 条

[1] Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial
Yagisawa, Masataka
Taniguchi, Hiroya
Satoh, Taroh
Kadowaki, Shigenori
Sunakawa, Yu
Nishina, Tomohiro
Komatsu, Yoshito
Esaki, Taito
Sakai, Daisuke
Doi, Ayako
Kajiwara, Takeshi
Ono, Hiromi
Asano, Masatoshi
Hirano, Nami
Odegaard, Justin
Fujii, Satoshi
Nomura, Shogo
Bando, Hideaki
Sato, Akihiro
Yoshino, Takayuki
Nakamura, Yoshiaki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (32)
[2] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
Modi, Shanu
Saura, Cristina
Yamashita, Toshinari
Park, Yeon Hee
Kim, Sung-Bae
Tamura, Kenji
Andre, Fabrice
Iwata, Hiroji
Ito, Yoshinori
Tsurutani, Junji
Sohn, Joohyuk
Denduluri, Neelima
Perrin, Christophe
Aogi, Kenjiro
Tokunaga, Eriko
Im, Seock-Ah
Lee, Keun Seok
Hurvitz, Sara A.
Cortes, Javier
Lee, Caleb
Liu, Yali
Zhang, Lin
Shahidi, Javad
Yver, Antoine
Baselga, Jose
Krop, Ian E.
CANCER RESEARCH, 2021, 81 (04)
[3] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Makker, V.
Lee, J-Y.
Oh, D-Y.
Oaknin, A.
Puvvada, S. D.
Cecchi, F.
Mcewen, R.
Michelini, F.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
[4] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
Modi, S.
Glass, B.
Prakash, A.
Taylor-Weiner, A.
Elliott, H.
Wapinski, I.
Sugihara, M.
Saito, K.
Kerner, J. Kaplan
Phillips, R.
Shibutani, T.
Honda, K.
Khosla, A.
Beck, A. H.
Cogswell, J.
ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
[5] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
Wysocki, Piotr Jan
Jung, Kyung Hae
Oh, Do-Youn
Doroshow, Deborah Blythe
Artamonova, Elena
Mammatas, Lemonitsa
Su, Po-Jung
Moiseyenko, Vladimir
Penkov, Konstantin
Stroyakovskiy, Daniil
Bartolome, Jorge
Siena, Salvatore
Fielding, Anitra
Jung, Lindsey
Michelini, Flavia
Puvvada, Soham D.
Makker, Vicky
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K.
Sang-We, K.
Kubo, T.
Goto, Y.
Ahn, M-J.
Planchard, D.
Kim, D-W.
Yang, J. C-H.
Yang, T-Y.
Pereira, K. M. C.
Saxena, K.
Shiga, R.
Cheng, Y.
Aregay, M.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
[7] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Li, B. T.
Meric-Bernstam, F.
Bardia, A.
Naito, Y.
Siena, S.
Aftimos, P. G.
Anderson, I.
Curigliano, G.
De Miguel Luken, M. J.
Kalra, M.
Oh, D-Y.
Park, J. O.
Postel-Vinay, S.
Rha, S. Y.
Satoh, T.
Spanggaard, I.
Michelini, F.
Smith, A.
Machado, K. Kalil
Saura Manich, C.
ANNALS OF ONCOLOGY, 2023, 34 : S459 - S460
[8] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial
Cheng, Ying
Wu, Lin
Fang, Yong
Fan, Yun
Li, Xingya
Zhang, Mingjun
Yu, Yan
Yao, Yu
Xu, Ruilian
Guo, Jun
Yang, Huaping
Fang, Jian
Luo, Feng
Min, Xuhong
Tang, Ke-Jing
Hu, Jie
Chen, Yunru
Mao, Rui
Zhang, Victor
Li, Dairong
CANCER RESEARCH, 2024, 84 (07)
[9] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Shen, L.
Chen, P.
Lu, J.
Wan, Y.
Zheng, Y.
Ye, F.
Yang, J.
Liu, Y.
Pan, H.
Chen, H.
Sun, M.
Fan, Q.
Yuan, Y.
Chen, K.
Sun, Z.
Tian, H.
Ye, X.
Peng, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1543

← 1 →